Alternative Names: A (H7N9) vaccine - Novavax; A(H7N9) influenza vaccine candidate - Novavax; H7N9 Virus-Like Particle (VLP) Influenza vaccine (recombinant) - Novavax; H7N9 VLP vaccine - Novavax; Monovalent VLP influenza H7N9 vaccine - Novavax; Pandemic H7N9 + Matrix-M™ influenza vaccine...
has announced positive results from second stage of a human clinical trial of its virus-like particle (VLP) vaccine against pandemic influenza. The vaccine is designed to protect individuals against the H5N1 A/Indonesia/05/2005 avian influenza strain which killed many people. According to company ...
today announced that it will present on its lead vaccine candidates, NVX-CoV2373, NanoFlu™ and ResVax™, the Company’s COVID-19, influenza and respiratory syncytial virus (RSV) vaccines.
et al. ISCOMATRIXTM adjuvant promotes epitope spreading and antibody affinity maturation of influenza A H7N9 virus like particle vaccine that correlate with virus neutralization in humans. Vaccine 33, 3953–3962 (2015). Article CAS PubMed Google Scholar Datoo, M. S. et al. Efficacy of a low...
FIG. 2 shows antigen specific antibody responses against influenza virus micelles as described in the text were tested in ELISA (log Titre) in the IgG1 (A) and IgG2a (B) subclasses. Mice (female NMRI) were immunised weeks 0 and 4 with the vaccine formulations described in Table 2 i.e....
1. A method of increasing the efficiency of influenza virus-like particle (VLP) production comprising expressing an avian influenza matrix (M1) protein and at least one non-avian influenza protein in a host cell, wherein the avian influenza M1 protein is derived from A/Indonesia/5/05 influenza...
Influenza Combination (CIC) and stand-alone influenza vaccine candidates. The clinical hold is due to a spontaneous report of a serious adverse event (SAE) of motor neuropathy in a single CIC Phase 2 trial participant outside of the U.S. who received th...
The article reports on the condition of Novavax Inc.'s Phase II clinical trial on its seasonal influenza virus-like particle vaccine (VLP) in Europe. It mentions that Novovax has recently partnered with ROVI Pharmaceutical Laboratories SA and cites the financial support rendered by ROVI for the...
Journal of Gerontological Nursing | Influenza Vaccine Trial Shows Positive Results for Older AdultsNovavax, Inc.鈥檚 trivalent seasonal influenza virus-like-particle (VLP)-based vaccine candidate has been found to be safe and immunogenic against the 2009鈥 2010 seasonal influenza virus strains in ...
Novavax and Sanofi Announce Co-exclusive Licensing Agreement to Co-commercialize COVID-19 Vaccine and Develop Novel COVID-19-Influenza Combination Vaccines Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ ...